Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours.

NCT06003621 is registered in ClinicalTrials.gov with Omico as lead sponsor.

NCT NCT06003621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06003621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours.
Lead sponsor
Omico
Phase
Phase 2
Overall status
Recruiting
Start date
December 15, 2023
Completion date
November 1, 2028
Enrollment
96 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult